Illumina (ILMN) financials

Life Sciences Tools & Services · NASDAQ · Health Care

$202.61 +2.33% Close Nov 17, 2026 Live

TrendArc score 50 of 100 · Health 8.6 · Momentum 2.8 · Moat 4.6 · scored Nov 17, 2026 · How the score works

Illumina revenue and earnings by year

Illumina's revenue was $4.34 billion in the fiscal year to December 28, 2025, down 0.7% from the year before. Net income was $850 million, 19.6% of revenue. Since the fiscal year to January 1, 2017, revenue has grown 6.8% a year on average.

RevenueNet income
$0
2017201720182019202120222023202320242025

Fiscal years, each labelled by the calendar year it ended in.

What stands out

  • Revenue fell in each of the last 3 fiscal years, from $4.6 billion in the fiscal year to January 2023 to $4.3 billion in the fiscal year to December 2025.

Each sentence is written by a fixed rule from the figures on this page.

Income statement, the last 10 fiscal years

In billions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toDec 2025Dec 2024Dec 2023Jan 2023Jan 2022Jan 2021Dec 2019Dec 2018Dec 2017Jan 2017
Revenue4.344.374.504.584.533.243.543.332.752.40
Revenue growth-0.7%-2.9%-1.7%1.3%39.7%-8.6%6.3%21.1%14.8%—
Gross profit2.872.862.742.973.152.202.472.301.831.67
Gross margin66.1%65.4%60.9%64.8%69.7%68.0%69.6%69.0%66.4%69.5%
Operating income0.81-0.83-1.07-4.18-0.120.580.980.880.610.59
Operating margin18.6%-19.1%-23.7%-91.2%-2.7%17.9%27.8%26.5%22.0%24.5%
Net income0.85-1.22-1.16-4.400.760.661.000.830.730.46
Net margin19.6%-28.0%-25.8%-96.1%16.8%20.3%28.3%24.8%26.4%19.3%
Diluted EPS$5.45-$7.66-$7.14-$27.22$4.88$4.33$6.57$5.41$4.80$3.01
Free cash flow0.930.710.280.110.340.890.840.850.560.51

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app, under Fundamentals on the full chart: open ILMN in TrendArc Charts.

Illumina revenue and margins against its peers

Each company's newest fiscal year; some end in a different month. Growth is on the fiscal year before.
CompanyFiscal year toRevenueRevenue growthOperating marginNet margin
IlluminaILMN Dec 2025 $4.34B -0.7%18.6%19.6%
Mettler ToledoMTD Dec 2025 $4.03B 4.0%27.3%21.6%
IQVIAIQV Dec 2025 $16.3B 5.9%13.4%8.3%
WatersWAT Dec 2025 $3.17B 7.0%25.4%20.3%
Agilent TechnologiesA Oct 2025 $6.95B 6.7%21.3%18.8%
Charles River LaboratoriesCRL Dec 2025 $4.02B -0.9%0.6%-3.6%
Bio-TechneTECH Jun 2026 $1.22B -0.4%20.7%15.0%
Peer median4.9%21.0%16.9%

See also: ILMN valuation and P/E history · ILMN returns

No forecast, no recommendation. This page describes Illumina from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.